1. Home
  2. CEPU vs DFTX Comparison

CEPU vs DFTX Comparison

Compare CEPU & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Central Puerto S.A. (each represents ten)

CEPU

Central Puerto S.A. (each represents ten)

HOLD

Current Price

$15.07

Market Cap

2.1B

Sector

Utilities

ML Signal

HOLD

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$23.59

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CEPU
DFTX
Founded
1989
N/A
Country
Argentina
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Sector
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.7B
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
CEPU
DFTX
Price
$15.07
$23.59
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
8
Target Price
$17.50
$38.50
AVG Volume (30 Days)
321.8K
1.5M
Earning Date
05-15-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$10.11
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$12.24
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.43
$14.62
52 Week High
$18.50
$26.25

Technical Indicators

Market Signals
Indicator
CEPU
DFTX
Relative Strength Index (RSI) 52.42 56.46
Support Level $14.84 $16.37
Resistance Level $15.56 $26.25
Average True Range (ATR) 0.70 1.10
MACD 0.19 0.13
Stochastic Oscillator 55.77 72.66

Price Performance

Historical Comparison
CEPU
DFTX

About CEPU Central Puerto S.A. (each represents ten)

Central Puerto SA is a power generation company. It is mainly engaged in electric power generation and commercialization. The company is also involved in the natural gas distribution public sector service in the Cuyo and Centro regions in Argentina. The Group has four reporting segments which includes electric power generation from conventional sources, electric power generation from renewable sources, natural gas transport and distribution, and forest activity. The company derives maximum revenue from Electric Power Generation from conventional sources segment.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Share on Social Networks: